Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

The Women's Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study: Description and Baseline Characteristics of Participants.

Paskett ED, Caan BJ, Johnson L, Bernardo BM, Young GS, Pennell ML, Ray RM, Kroenke CH, Porter PL, Anderson GL.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):125-137. doi: 10.1158/1055-9965.EPI-17-0581. Epub 2018 Jan 29.

PMID:
29378785
2.

Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients.

Korde LA, Doody DR, Hsu L, Porter PL, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):165-173. doi: 10.1158/1055-9965.EPI-17-0556. Epub 2017 Dec 18.

PMID:
29254937
3.

Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, Berger C, Kosasih PL, Rajan A, Sommermeyer D, Porter PL, Riddell SR.

Clin Cancer Res. 2017 Jun 15;23(12):3061-3071. doi: 10.1158/1078-0432.CCR-16-2083. Epub 2016 Nov 16.

4.

Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Atkinson C, Ray RM, Li W, Lin MG, Gao DL, Shannon J, Stalsberg H, Porter PL, Frankenfeld CL, Wähälä K, Thomas DB, Lampe JW.

Nutr Res. 2016 Aug;36(8):863-71. doi: 10.1016/j.nutres.2016.03.008. Epub 2016 Mar 30.

5.

Improving Breast Ultrasound Interpretation in Uganda Using a Condensed Breast Imaging Reporting and Data System.

Scheel JR, Peacock S, Orem J, Bugeza S, Muyinda Z, Porter PL, Wood WC, Comis RL, Lehman CD.

Acad Radiol. 2016 Oct;23(10):1271-7. doi: 10.1016/j.acra.2016.05.018. Epub 2016 Jun 17.

PMID:
27325412
6.

Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.

Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, Li CI.

Breast Cancer Res Treat. 2016 Jun;157(3):545-54. doi: 10.1007/s10549-016-3825-9. Epub 2016 May 24.

7.

An unsupervised MVA method to compare specific regions in human breast tumor tissue samples using ToF-SIMS.

Bluestein BM, Morrish F, Graham DJ, Guenthoer J, Hockenbery D, Porter PL, Gamble LJ.

Analyst. 2016 Mar 21;141(6):1947-57. doi: 10.1039/c5an02406d.

8.

ACR BI-RADS Use in Low-Income Countries: An Analysis of Diagnostic Breast Ultrasound Practice in Uganda.

Scheel JR, Nealey EM, Orem J, Bugeza S, Muyinda Z, Nathan RO, Porter PL, Lehman CD.

J Am Coll Radiol. 2016 Feb;13(2):163-9. doi: 10.1016/j.jacr.2015.07.035. Epub 2015 Sep 26. No abstract available.

PMID:
26419306
9.

An international study to increase concordance in Ki67 scoring.

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO.

Mod Pathol. 2015 Jun;28(6):778-86. doi: 10.1038/modpathol.2015.38. Epub 2015 Feb 20.

10.

Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy.

Zhao H, Faltermeier CM, Mendelsohn L, Porter PL, Clurman BE, Roberts JM.

Oncotarget. 2014 Dec 30;5(24):12704-14.

11.

Autonomous stimulation of cancer cell plasticity by the human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells.

Cai X, Dai Z, Reeves RS, Caballero-Benitez A, Duran KL, Delrow JJ, Porter PL, Spies T, Groh V.

PLoS One. 2014 Oct 7;9(10):e108942. doi: 10.1371/journal.pone.0108942. eCollection 2014.

12.

Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.

Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE.

Breast Cancer Res Treat. 2014 Jun;145(2):481-9. doi: 10.1007/s10549-014-2960-4. Epub 2014 Apr 20.

13.

Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.

Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, Li CI.

Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):755-64. doi: 10.1158/1055-9965.EPI-13-0944. Epub 2014 Mar 14.

14.

Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years.

Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE.

JAMA Intern Med. 2013 Sep 23;173(17):1629-37. doi: 10.1001/jamainternmed.2013.9071.

15.

Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age.

McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI.

Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1529-37. doi: 10.1158/1055-9965.EPI-13-0414. Epub 2013 Jul 5.

16.

Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE.

Breast Cancer Res Treat. 2013 Jan;137(2):579-87. doi: 10.1007/s10549-012-2365-1. Epub 2012 Dec 9.

17.

Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age.

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE.

Cancer Res. 2012 Apr 15;72(8):2028-35. doi: 10.1158/0008-5472.CAN-11-4064. Epub 2012 Feb 27.

18.

Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer.

Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, O'Meara ES, Li CI.

Ann Epidemiol. 2012 May;22(5):340-8. doi: 10.1016/j.annepidem.2012.02.002. Epub 2012 Feb 25.

19.

Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer.

Malone KE, Daling JR, Doody DR, O'Brien C, Resler A, Ostrander EA, Porter PL.

Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2560-71. doi: 10.1158/1055-9965.EPI-11-0781. Epub 2011 Sep 29.

20.

Assessment of palindromes as platforms for DNA amplification in breast cancer.

Guenthoer J, Diede SJ, Tanaka H, Chai X, Hsu L, Tapscott SJ, Porter PL.

Genome Res. 2012 Feb;22(2):232-45. doi: 10.1101/gr.117226.110. Epub 2011 Jul 13.

21.

Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative.

Harford JB, Otero IV, Anderson BO, Cazap E, Gradishar WJ, Gralow JR, Kane GM, Niëns LM, Porter PL, Reeler AV, Rieger PT, Shockney LD, Shulman LN, Soldak T, Thomas DB, Thompson B, Winchester DP, Zelle SG, Badwe RA.

Breast. 2011 Apr;20 Suppl 2:S20-9. doi: 10.1016/j.breast.2011.02.007. Epub 2011 Mar 4.

PMID:
21376593
22.

Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women.

Loo LW, Wang Y, Flynn EM, Lund MJ, Bowles EJ, Buist DS, Liff JM, Flagg EW, Coates RJ, Eley JW, Hsu L, Porter PL.

Breast Cancer Res Treat. 2011 May;127(1):297-308. doi: 10.1007/s10549-010-1297-x. Epub 2011 Jan 25.

23.

Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.

Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI.

Cancer Causes Control. 2011 Mar;22(3):399-405. doi: 10.1007/s10552-010-9709-0. Epub 2010 Dec 24.

24.

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer.

Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, Malone KE.

Breast Cancer Res Treat. 2011 Apr;126(3):749-61. doi: 10.1007/s10549-010-1174-7. Epub 2010 Sep 29.

25.

Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL sample preparation.

Ton CC, Vartanian N, Chai X, Lin MG, Yuan X, Malone KE, Li CI, Dawson A, Sather C, Delrow J, Hsu L, Porter PL.

Breast Cancer Res Treat. 2011 Feb;125(3):879-83. doi: 10.1007/s10549-010-1159-6. Epub 2010 Sep 15.

26.

Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk.

Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI.

Breast Cancer Res Treat. 2011 Apr;126(3):671-8. doi: 10.1007/s10549-010-1148-9. Epub 2010 Sep 3.

27.

Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.

Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF.

Am J Pathol. 2010 Apr;176(4):1639-47. doi: 10.2353/ajpath.2010.090711. Epub 2010 Feb 11.

28.

Global trends in breast cancer incidence and mortality.

Porter PL.

Salud Publica Mex. 2009;51 Suppl 2:s141-6. Review.

29.

Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer.

Li CI, Daling JR, Porter PL, Tang MT, Malone KE.

J Clin Oncol. 2009 Nov 10;27(32):5312-8. doi: 10.1200/JCO.2009.23.1597. Epub 2009 Sep 8.

30.

Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer.

Li CI, Daling JR, Porter PL, Tang MT, Malone KE.

Cancer Res. 2009 Sep 1;69(17):6865-70. doi: 10.1158/0008-5472.CAN-09-1355. Epub 2009 Aug 25. Erratum in: Cancer Res. 2010 Mar 1;70(5):2140. Cancer Res. 2010 Jan 15;70(2):853.

31.

The epidemiology of triple-negative breast cancer, including race.

Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW.

Cancer Causes Control. 2009 Sep;20(7):1071-82. doi: 10.1007/s10552-009-9331-1. Epub 2009 Apr 3.

32.

Risk factors for triple-negative breast cancer in women under the age of 45 years.

Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1157-66. doi: 10.1158/1055-9965.EPI-08-1005. Epub 2009 Mar 31.

33.

Reproductive factors, age at maximum height, and risk of three histologic types of breast cancer.

Beaber EF, Holt VL, Malone KE, Porter PL, Daling JR, Li CI.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3427-34. doi: 10.1158/1055-9965.EPI-08-0641. Erratum in: Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3138.

34.

Migraine in postmenopausal women and the risk of invasive breast cancer.

Mathes RW, Malone KE, Daling JR, Davis S, Lucas SM, Porter PL, Li CI.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3116-22. doi: 10.1158/1055-9965.EPI-08-0527.

35.

Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer.

Phipps AI, Malone KE, Porter PL, Daling JR, Li CI.

Cancer. 2008 Oct 1;113(7):1521-6. doi: 10.1002/cncr.23786.

36.

Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer.

Loo LW, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL.

Genes Chromosomes Cancer. 2008 Dec;47(12):1049-66. doi: 10.1002/gcc.20610.

37.

Effect of prediagnostic alcohol consumption on survival after breast cancer in young women.

Reding KW, Daling JR, Doody DR, O'Brien CA, Porter PL, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1988-96. doi: 10.1158/1055-9965.EPI-07-2897. Epub 2008 Jul 29.

38.

Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women.

Phipps AI, Malone KE, Porter PL, Daling JR, Li CI.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2078-86. doi: 10.1158/1055-9965.EPI-08-0206. Epub 2008 Jul 29.

39.

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW.

Breast Cancer Res Treat. 2009 Jan;113(2):357-70. doi: 10.1007/s10549-008-9926-3. Epub 2008 Mar 7.

PMID:
18324472
40.

Case-control study of fetal microchimerism and breast cancer.

Gadi VK, Malone KE, Guthrie KA, Porter PL, Nelson JL.

PLoS One. 2008 Mar 5;3(3):e1706. doi: 10.1371/journal.pone.0001706.

41.

Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer.

Mathes RW, Malone KE, Daling JR, Porter PL, Li CI.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):67-72. doi: 10.1158/1055-9965.EPI-07-0765.

42.

Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas.

Li CI, Malone KE, Porter PL, Lawton TJ, Voigt LF, Cushing-Haugen KL, Lin MG, Yuan X, Daling JR.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50. doi: 10.1158/1055-9965.EPI-07-0558. Erratum in: Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2803.

43.

Plasma isoflavones and fibrocystic breast conditions and breast cancer among women in Shanghai, China.

Lampe JW, Nishino Y, Ray RM, Wu C, Li W, Lin MG, Gao DL, Hu Y, Shannon J, Stalsberg H, Porter PL, Frankenfeld CL, Wähälä K, Thomas DB.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2579-86.

44.

High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer.

Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, Ellis IO, Porter PL, Tavaré S, Brenton JD, Ylstra B, Caldas C.

Genome Biol. 2007;8(10):R215.

45.

Oral contraceptives and survival in breast cancer patients aged 20 to 54 years.

Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Moorman PG, Kaufman JS, Cai J, Porter PL, Brinton LA, Eley JW, Coates RJ.

Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1822-7.

46.

p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy.

Porter PL, Barlow WE, Yeh IT, Lin MG, Yuan XP, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF.

J Natl Cancer Inst. 2006 Dec 6;98(23):1723-31.

47.

General and abdominal obesity and survival among young women with breast cancer.

Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, Swanson CA, Brinton LA, Eley JW, Coates RJ.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1871-7.

48.

Association between reproductive factors and breast cancer survival in younger women.

Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Kaufman JS, Moorman PG, Cai J, Olshan AF, Porter PL, Brinton LA, Eley JW, Coates RJ.

Breast Cancer Res Treat. 2007 May;103(1):93-102. Epub 2006 Sep 27.

PMID:
17004111
49.

Recreational physical activity and survival among young women with breast cancer.

Abrahamson PE, Gammon MD, Lund MJ, Britton JA, Marshall SW, Flagg EW, Porter PL, Brinton LA, Eley JW, Coates RJ.

Cancer. 2006 Oct 15;107(8):1777-85.

50.

Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer.

Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grünwald V, Kamino K, Wilkens L, Lehmann U, Buer J, Geffers R, Kubicka S, Manns MP, Porter PL, Roberts JM, Malek NP.

Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14009-14. Epub 2006 Sep 11.

Supplemental Content

Loading ...
Support Center